Regencell Bioscience (NASDAQ:RGC) Lowered to Sell Rating by Wall Street Zen

Regencell Bioscience (NASDAQ:RGC) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Stock Performance

RGC opened at $5.02 on Friday. Regencell Bioscience has a one year low of $4.51 and a one year high of $69.00. The company has a fifty day moving average price of $16.25 and a 200-day moving average price of $24.13.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

A number of hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience during the 4th quarter worth $92,000. Amundi bought a new position in Regencell Bioscience in the first quarter valued at $219,000. Hudson Bay Capital Management LP bought a new position in Regencell Bioscience in the fourth quarter valued at $275,000. Bank of America Corp DE raised its position in Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares in the last quarter. Finally, Vident Advisory LLC raised its position in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares in the last quarter. 0.13% of the stock is owned by institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.